Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HBIO 
Harvard Bioscience Inc (HBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: HBIO (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 64.28% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.03M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta 1.55 | 52 Weeks Range 0.28 - 3.60 | Updated Date 07/4/2025 |
52 Weeks Range 0.28 - 3.60 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -63.52% | Operating Margin (TTM) -7.46% |
Management Effectiveness
Return on Assets (TTM) -2.38% | Return on Equity (TTM) -138.8% |
Valuation
Trailing PE - | Forward PE 14.93 | Enterprise Value 59089826 | Price to Sales(TTM) 0.22 |
Enterprise Value 59089826 | Price to Sales(TTM) 0.22 | ||
Enterprise Value to Revenue 0.65 | Enterprise Value to EBITDA 179.26 | Shares Outstanding 44213700 | Shares Floating 33973842 |
Shares Outstanding 44213700 | Shares Floating 33973842 | ||
Percent Insiders 8.27 | Percent Institutions 69.66 |
Upturn AI SWOT
Harvard Bioscience Inc
Company Overview
History and Background
Harvard Bioscience, Inc. (HBIO) was founded in 1901. Initially focused on kymographs and physiological recorders, it has evolved through acquisitions and internal development to offer a broader range of tools for life science research and clinical applications.
Core Business Areas
- Cellular and Molecular Products: Includes electrophoresis equipment, imaging systems, and other tools for cell and molecular biology research.
- Physiology Products: Offers instruments for measuring physiological parameters in animals and humans, such as ventilators, pumps, and data acquisition systems.
- Data Acquisition & Analysis Software: Provides data analysis for Physiology and Cellular and Molecular research
- Preclinical Solutions: Offerings for small animal in vivo studies (behavior, physiology, imaging etc.)
Leadership and Structure
Harvard Bioscience is led by a CEO and a board of directors. The organizational structure is departmentalized, with divisions focusing on product development, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- Harvard Apparatus Ventilators: Used for rodent and small animal ventilation in research. Market share is estimated to be between 20-25%. Competitors include Kent Scientific and Hugo Sachs Elektronik.
- DSI telemetry implants: Wireless physiological monitoring technology for preclinical research. Revenue are significant, but public market share data are difficult to acquire. Competitors include Transoma Medical and emka TECHNOLOGIES.
Market Dynamics
Industry Overview
The life science tools market is driven by increasing R&D spending in pharmaceuticals, biotechnology, and academic research. Key trends include automation, miniaturization, and the integration of data analytics.
Positioning
Harvard Bioscience occupies a niche position in the market, focusing on specialized tools for specific applications. Their competitive advantage lies in their established brand and reputation for quality.
Total Addressable Market (TAM)
The TAM for life science tools is estimated at over $100 billion. Harvard Bioscience addresses a portion of this market with its specialized product offerings. Its TAM is likely in the range of $2-5B
Upturn SWOT Analysis
Strengths
- Established brand reputation
- Specialized product portfolio
- Strong customer relationships in research institutions
Weaknesses
- Smaller scale compared to larger competitors
- Dependence on research funding cycles
- Limited global presence
Opportunities
- Expanding into emerging markets
- Developing new products for personalized medicine
- Acquiring complementary technologies
Threats
- Increased competition from larger players
- Changes in research funding priorities
- Technological obsolescence
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Agilent Technologies (A)
Competitive Landscape
Harvard Bioscience faces intense competition from larger, more diversified companies. Their advantage lies in their specialized expertise and focus on niche markets. However the overall Market Share is less than 1% of TAM.
Major Acquisitions
Data Sciences International (DSI)
- Year: 2005
- Acquisition Price (USD millions): 93
- Strategic Rationale: Expanded HBIO's portfolio into preclinical monitoring technologies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been inconsistent, dependent on acquisitions and market conditions.
Future Projections: Analyst estimates vary. Future growth will likely depend on successful product development and market expansion.
Recent Initiatives: Check recent press releases and investor presentations for strategic initiatives.
Summary
Harvard Bioscience is a niche player in the life science tools market with a long history. Their specialization provides some advantage, but they face stiff competition from much larger companies. Financial performance has been inconsistent. Careful product development and expansion into high-growth markets are needed for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Investor Presentations, Press Releases, Market Research Reports, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harvard Bioscience Inc
Exchange NASDAQ | Headquaters Holliston, MA, United States | ||
IPO Launch date 2000-12-07 | President, CEO & Chairman Mr. James W. Green | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 330 | |
Full time employees 330 | |||
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.